Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.
Paton, NI; Kityo, C; Thompson, J; Nankya, I; Bagenda, L; Hoppe, A; Hakim, J; Kambugu, A; van Oosterhout, JJ; Kiconco, M; Bertagnolio, S; Easterbrook, PJ; Mugyenyi, P; Walker, AS; Europe Africa Research Network for Evaluation of Second-line The; COLLABORATORS; Agweng, E; Awio, P; Bakeinyaga, G; Isabirye, C; Kabuga, U; Kasuswa, S; Katuramu, M; Kityo, C; Kiweewa, F; Kyomugisha, H; Lutalo, E; Mugyenyi, P; Mulima, D; Musana, H; ... view all 293 authors
mesheuropmc: immune system diseases | virus diseases
Cross-resistance after first-line antiretroviral therapy (ART) failure is expected to impair activity of nucleoside reverse-transcriptase inhibitors (NRTIs) in second-line therapy for patients with HIV, but evidence for the effect of cross-resistance on virological outc... View more
1 Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006; 368: 505-10.
2 Joint United Nations Programme on HIV/AIDS. Global AIDS Update. 2016. http://www.unaids.org/en/resources/ documents/2016/Global-AIDS-update-2016 (accessed Nov 26, 2016).
3 WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2016.
4 Panel on Antiretroviral Guidelines for Adults and Adolescents. United States Department of Health and Human Services. http://aidsinfo.nih.gov/contentfiles/lvguidelines/ AdultandAdolescentGL.pdf (accessed Feb 21, 2017).
5 European AIDS Clinical Society. Guidelines 8.0. 2015. http://www.eacsociety.org/files/2015_eacsguidelines_8_0-english_ rev-20160124.pdf (accessed Feb 21, 2017).
6 Churchill D, Waters L, Ahmed N, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. HIV Med 2016; 17 (suppl 4): s2-104.
7 Paton NI, Kityo C, Hoppe A, et al. Assessment of second-line antiretroviral regimens for HIV therapy in Africa. N Engl J Med 2014; 371: 234-47.
8 Manasa J, Lessells RJ, Skingsley A, et al. High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa. PLoS One 2013; 8: e72152.
9 Kyeyune F, Nankya I, Metha S, et al. Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period. AIDS 2013; 27: 1899-909.
10 Frentz D, Boucher CA, Assel M, et al. Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. PLoS One 2010; 5: e11505.